Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) were down 28.6% during mid-day trading on Thursday. The company traded as low as C$0.03 and last traded at C$0.03. Approximately 231,000 shares were traded during trading, an increase of 52% from the average daily volume of 151,812 shares. The stock had previously closed at C$0.04.
Kane Biotech Trading Down 14.3%
The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The stock has a market capitalization of C$6.15 million, a PE ratio of -1.50 and a beta of 0.79. The business’s 50-day moving average is C$0.03 and its two-hundred day moving average is C$0.03.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
